Page 8 - எங்களுக்கு தேசிய நிறுவனம் ஆஃப் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19 Top-line results expected in the coming weeks Opaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill, demonstrated potent inhibition of Beta and Gamma variants and is expected to be effective against emerging variants, including Delta and Delta Plus RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640)

South africaSouth africanRedhill biopharmaMarkl levittUs national institute of healthRedhill biopharma ltdHill biopharmaMedical directorWorld health organization ordinal scaleClinical improvementOrphan drugஎங்களுக்கு தேசிய நிறுவனம் ஆஃப் ஆரோக்கியம்மருத்துவ இயக்குனர்மருத்துவ முன்னேற்றம்ஆர்ஃபந் மருந்து